This PRMT5 Target Evaluation Report is generated from PatSnap Target & Disease MCP and Clinical Trials MCP data. The report highlights PRMT5 as a clinically active oncology target, especially in MTAP-deleted tumors where MTA-cooperative PRMT5 inhibition has created a differentiated synthetic-lethality strategy.

This CDK2 Target Evaluation Report is generated from PatSnap MCP data. CDK2 is an increasingly important cell-cycle target in breast cancer, especially for HR+/HER2- disease after CDK4/6 inhibitor exposure and for tumors with cyclin E or CCNE1-driven biology.

This GPRC5D Target Evaluation Report is generated from PatSnap MCP data. In multiple myeloma, GPRC5D has become a major post-BCMA and BCMA-adjacent target, with 110 Clinical Trials MCP trial records and 143 result records spanning bispecific antibodies, cellular therapies, and safety-management strategies.

This ROR1 Target Evaluation Report is generated from PatSnap Target & Disease MCP and Clinical Trials MCP data. ROR1 is an oncology target with compelling tumor-associated expression and active clinical exploration in CLL, but the evidence base is still earlier and more selective than mature hematology targets.

This PSMA Target Evaluation Report is generated from PatSnap MCP data. FOLH1 / PSMA is one of the most clinically validated prostate cancer targets, with a dense radioligand, imaging, and targeted-therapy ecosystem reflected by 577 Clinical Trials MCP trial records and 405 result records.

This EPAS1 / HIF-2α Target Evaluation Report is generated from PatSnap Target & Disease MCP and Clinical Trials MCP data. For renal cell carcinoma, the target combines strong pathway biology, approved-class validation around HIF-2α inhibition, and an active clinical race around belzutifan combinations, zanzalintinib, casdatifan, and neoadjuvant strategies.

EZH2 is a clinically relevant lymphoma target with opportunity in immune-epigenetic combinations.

MDM2 is niche but compelling in liposarcoma, where focused evidence matters more than raw trial volume.

FGFR3 is a focused urothelial carcinoma target with biomarker-driven opportunity.

VEGFR2 is validated in RCC, but new value comes from regimen and sequencing design.

BCL2 is validated in CLL; modern value depends on combination, MRD, and sequencing strategy.

BTK is a deeply validated CLL target with intense competition and meaningful white space in resistance, safety, and fixed-duration combinations.